[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 66 of about 66
1. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • They have a generally poor prognosis and often develop recurrent disease.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


2. Zhang C, Li XP, Cui H, Shen DH, Wei LH: Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses. J Zhejiang Univ Sci B; 2008 Jun;9(6):435-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT).
  • Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide).
  • The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively.
  • There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P<0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P<0.05).
  • Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P<0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival.
  • CONCLUSION: Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy.
  • The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. China / epidemiology. Combined Modality Therapy. Cystadenocarcinoma, Papillary / metabolism. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / mortality. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / therapy. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Prognosis. Receptor, ErbB-2 / metabolism. Survival Rate. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):99-104 [11426969.001]
  • [Cites] Am J Obstet Gynecol. 1959 Jan;77(1):197-200 [13606191.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):148-54 [12694669.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):976-81 [15498644.001]
  • [Cites] Am J Surg Pathol. 1988 Nov;12(11):827-34 [3189692.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):1052-60 [11251959.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41 [14764027.001]
  • [Cites] Obstet Gynecol. 1990 Jan;75(1):89-95 [2296429.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):230-6 [2013445.001]
  • [Cites] Gynecol Oncol. 1993 Sep;50(3):347-51 [8406199.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):171-4 [8276289.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):854-63 [7518735.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):490-2 [7834614.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):55-8 [8690292.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1587-94 [9118043.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):141-6 [9367697.001]
  • [Cites] Obstet Gynecol. 1998 Feb;91(2):254-9 [9469285.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):230-9 [9826465.001]
  • [Cites] Obstet Gynecol Surv. 1999 May;54(5):323-35 [10234697.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):341-5 [11603217.001]
  • (PMID = 18543395.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2408695
  •  go-up   go-down


3. Muller M, Dupre PF, Lucas B, Simon H, Malhaire JP, Guillemet C, Dessogne P, Pradier O: [Carcinosarcoma of the ovary]. J Gynecol Obstet Biol Reprod (Paris); 2007 Jun;36(4):399-402
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian carcinosarcoma, also called malignant mixed mesodermal tumour, is a rare ovarian tumour representing less than two per cent of ovarian cancers.
  • Carcinosarcoma is an aggressive tumour, which associates some epithelial elements (carcinoma) with a stromal component (sarcoma).
  • This tumour can be found in the female genital tractus, mostly in the uterus.
  • The initial stage of the disease at the diagnostic is considered as the only prognostic factor.
  • There is no existing consensus concerning treatment.
  • Nevertheless, surgical treatment is paramount for the survival of patients.
  • Response rates to chemotherapy are about 20%.
  • [MeSH-major] Carcinosarcoma / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408876.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Dumortier J, Freyer G, Sasco AJ, Frappart L, Zénone T, Romestaing P, Trillet-Lenoir V: Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature. Ann Oncol; 2000 Mar;11(3):355-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature.
  • BACKGROUND: Anti oestrogenic treatment is widely used for breast cancer treatment and prevention of recurrence.
  • Although secondary endometrial cancers usually present as pure adenocarcinomas, other types of rare tumors have also been reported.
  • PATIENTS AND METHODS: Herein we describe the clinical, pathological as well as therapeutic aspects of a new case of endometrial mesodermal mixed tumor occurring after long-term tamoxifen therapy.
  • RESULTS: The present case occured five years after cessation of a five years tamoxifen treatment.
  • The patient failed to respond to doxorubicin and cyclophosphamide when combined to 5-fluorouracil (5-FU), but she reached complete response when the same two drugs were used with carboplatin, suggesting the potential usefullness of platinum derivatives.
  • CONCLUSIONS: A longer latency period might be observed for endometrial mesodermal mixed tumors as compared to adenocarcinomas and could justify a prolonged clinical and ultrasonographic follow-up of patients during and after tamoxifen treatment.
  • When indicated, chemotherapy might require the use of platinum derivatives in this particular type of secondary tumor.

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811505.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin
  • [Number-of-references] 24
  •  go-up   go-down


5. Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK: Malignant mixed mullerian tumor (MMMT) of the cervix. Gynecol Oncol; 2005 May;97(2):442-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor (MMMT) of the cervix.
  • OBJECTIVES: To characterize the clinical characteristics, therapeutic options, and potential outcomes in patients diagnosed with malignant mixed mullerian tumor (MMMT) of the uterine cervix.
  • METHODS: Five women ranging in age from 25 to 66 (mean 49.6 years) were diagnosed with MMMT of the cervix and treated at the University of Iowa Hospitals and Clinics between 1986 and 2001.
  • Data were retrospectively analyzed from available charts and pathological reports with particular attention to patient demographics, presenting symptoms, treatment, and follow-up.
  • FIGO disease staging at initial diagnosis included two patients with stage IB1 (ages 29 and 66 years), two patients with stage IB2 (ages 25 and 64 years), and one patient with stage IVB (age 64 years) MMMT of the cervix.
  • Organ-confined, early stage lesions (stages IB1 and IB2) responded well to regimens of either surgery alone or surgery plus radiation therapy, with no evidence of recurrent disease at last follow-up 28, 35, 42, and 65 months later, respectively.
  • The lone patient with advanced stage IVB disease, however, was unresponsive to both external beam radiation therapy and ifosfamide chemotherapy, and succumbed to disease within 5 months.
  • CONCLUSIONS: Cervical MMMT is an uncommon disease, but long-term survival is possible in organ-confined early stage disease with primary therapy.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863143.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


6. Deng L, Broaddus RR, McCampbell A, Shipley GL, Loose DS, Stancel GM, Pickar JH, Davies PJ: Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res; 2005 Dec 1;11(23):8258-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.
  • Here, we describe the expression pattern of a novel estrogen-induced gene, EIG121, in distinct types of endometrial cancer.
  • EXPERIMENTAL DESIGN: EIG121 was identified by cDNA microarray analysis of endometrial RNA from women receiving either placebo or estrogen replacement therapy.
  • The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples.
  • RESULTS: In postmenopausal endometrium, estrogen replacement therapy with Premarin and synthetic estrogen sulfate conjugates induced the expression of EIG121 2- and 3-fold, respectively.
  • In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors).
  • Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage.
  • Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors.
  • In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium.
  • CONCLUSIONS: Our results suggest that EIG121 is a good endometrial biomarker associated with a hyperestrogenic state and estrogen-related type I endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Estrogen Replacement Therapy. Estrogens / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Neoplasm Proteins / genetics
  • [MeSH-minor] Case-Control Studies. Endometrial Hyperplasia / genetics. Endometrial Hyperplasia / pathology. Estrogens, Conjugated (USP) / therapeutic use. Estrone / analogs & derivatives. Estrone / therapeutic use. Expressed Sequence Tags. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRONE .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322283.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NICHD NIH HHS / HD / 5T32 HD007324-18
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens; 0 / Estrogens, Conjugated (USP); 0 / KIAA1324 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 2DI9HA706A / Estrone; QTL48N278K / estrone sulfate
  •  go-up   go-down


7. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer; 2004 May 15;100(10):2148-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A review of clinicopathologic features and outcome in women with carcinosarcoma of the ovary (also known as malignant mixed mesodermal tumor [MMMT]) compared with a group of women with serous adenocarcinoma (SAC) of the ovary was conducted.
  • METHODS: Between 1984 and 2002, 1568 patients with epithelial ovarian carcinoma and 70 patients with ovarian carcinosarcoma underwent treatment at the Edinburgh Cancer Centre.
  • Analysis was performed on 65 patients with MMMT, and 746 patients with SAC were selected as a group for comparison.
  • Baseline variables were recorded prospectively and response to chemotherapy and progression-free and cause-specific survival between the groups were compared.
  • The objective response rate to platinum-based chemotherapy was found to be significantly lower in patients with carcinosarcoma (25% vs. 60%; P = 0.02).
  • Achieving optimal debulking at the time of initial surgery was found to be a highly significant factor in patients with carcinosarcoma with regard to determining outcome (median survival of 14.8 months for patients with optimally debulked International Federation of Gynecology and Obstetrics Stage III disease vs. 3.1 months for patients with suboptimally/nondebulked Stage III disease; P < 0.001).
  • CONCLUSIONS: Ovarian carcinosarcoma is a distinct entity with a poor prognosis.
  • Patients with carcinosarcoma differ from those with SAC with regard to having an older mean age of onset, an inferior response to platinum-based chemotherapy, and worse progression-free and cause-specific survival.
  • The extent of benefit from chemotherapy is unclear.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / mortality. Cystadenoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139057.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol; 2010 Jun 01;28(16):2727-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
  • PURPOSE: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor).
  • PATIENTS AND METHODS: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy.
  • Patients received paclitaxel at 175 mg/m(2) intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred.
  • Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Carboplatin / administration & dosage. Carboplatin / adverse effects. Confidence Intervals. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Immunohistochemistry. Infusions, Intravenous. Kaplan-Meier Estimate. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Probability. Prognosis. Program Evaluation. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):306-7 [9626805.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):177-85 [17822748.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):58-62 [17935761.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):268-70 [11606082.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):311-4 [11972393.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):774-8 [15350372.001]
  • [Cites] Ann Intern Med. 1973 Oct;79(4):604-5 [4748282.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Clin Oncol. 1985 Oct;8(5):350-2 [3840643.001]
  • [Cites] Biometrics. 1985 Sep;41(3):741-4 [4074823.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Cancer Treat Rep. 1987 Jun;71(6):661-2 [3034423.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):935-8 [2914299.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):372-8 [2548936.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):32-4 [2154921.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):6-10 [2159188.001]
  • [Cites] Invest New Drugs. 1991 Feb;9(1):93-4 [2026490.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):400-2 [8677914.001]
  • (PMID = 20421537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2881851
  •  go-up   go-down


9. Melilli GA, Nappi L, Carriero C, Lapresa M, Loizzi V, Caradonna F, Quaranta M, Putignano G: Malignant mixed mullerian tumor of the ovary: report of four cases. Eur J Gynaecol Oncol; 2001;22(1):67-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the ovary: report of four cases.
  • INTRODUCTION: Malignant mixed mullerian tumor (MMMT) of the ovary is an extremely rare gynaecologic neoplasm that represents 1% of the malignances of this organ.
  • Stage I disease is rare because it is asymptomatic in early stage.
  • CASE REPORTS: In the Department of Obstetrics and Gynecology of the University of Bari four cases of MMMT of the ovary were diagnosed.
  • Three patients were in stage IIIC and one of them was a homologous MMMT; the fourth patient was affected by a heterologous stage IV MMMT.
  • All women were treated with surgery and chemotherapy.
  • Two patients are alive 14 and 12 months after diagnosis.
  • CONCLUSIONS: The malignant mixed mullerian tumor (MMMT) of the ovary is a particularly aggressive tumor, especially in advanced stages.
  • The survival rate is very low in spite of surgery, chemotherapy and radiotherapy.
  • The optimal treatment for this neoplasm is unknown because of its rarity.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321500.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Hubalek M, Ramoni A, Mueller-Holzner E, Marth C: Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Gynecol Oncol; 2004 Oct;95(1):264-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
  • Especially rare endometrial tumors seem to develop more frequently under tamoxifen therapy.
  • A recent analysis showed a substantially higher risk for malignant mixed mesodermal tumor (MMMT; designated in the WHO classification of female genital tract neoplasms as carcinosarcoma) in association with tamoxifen intake.
  • CASE: We are reporting a case of a 40-year-old multiparous premenopausal woman who received tamoxifen 20 mg daily for 2 years after the surgical treatment of breast cancer and subsequent adjuvant chemotherapy.
  • Two years after initiation of tamoxifen treatment, the patient developed an MMMT of the uterus.
  • More than 64 months after radical hysterectomy, salpingo-oophorectomy, and pelvic lymphadenectomy, she remains recurrence-free for MMMT.
  • Unfortunately, she developed a local recurrence of her breast cancer in 2003.
  • After surgical treatment, she is currently being treated with anastrozole.
  • CONCLUSION: We are reporting a rare case of a premenopausal patient who developed a MMMT within short time of tamoxifen exposure for stage I breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Mixed Tumor, Mesodermal / chemically induced. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15385144.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


11. Takano M, Shibasaki T, Sato K, Aida S, Kikuchi Y: Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. Gynecol Oncol; 2003 Nov;91(2):444-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component.
  • OBJECTIVES: Hepatoid adenocarcinoma is a rare tumor and has the histological coexistence of well-differentiated adenocarcinoma and nests of hepatoid cells with immunoreactivity for alpha-fetoprotein (AFP).
  • A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature.
  • Histologically, the tumor was composed of endometrioid adenocarcinoma, neoplastic hepatoid cells, and sarcoma component including leiomyosarcoma and rhabdomyosarcoma.
  • After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.
  • CONCLUSIONS: This is, to our knowledge, the first report of malignant mixed Mullerian tumor of the uterus with an AFP-producing hepatoid adenocarcinoma component.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  •  go-up   go-down


12. Lee SH, Kim J, Kim JH, Lee KH, Park JS, Hur SY: Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review. Eur J Gynaecol Oncol; 2010;31(4):462-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review.
  • Malignant mixed mesodermal tumors (MMMTs) are composed of carcinomatous and sarcomatous components and have an aggressive metastatic potential, resulting in a poor prognosis.
  • Due to the rarity of MMMTs arising from the cervix, there is no consensus regarding treatment, prognosis, and outcome; however, aggressive surgical cytoreduction, combined with adjuvant platinum-based chemotherapy and/or radiotherapy, is recommended as the treatment of choice for MMMTs of the cervix.
  • Cervical MMMTs are more often confined to the uterus at the time of diagnosis and frequently have non-glandular epithelial components.
  • A case of an immunohistochemically confirmed primary MMMT of the cervix, including components of a rhabdomyosarcoma, is reported.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Rhabdomyosarcoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882897.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


13. Goldman NA, de Los Angeles MM, Jones JG, Goldberg GL: Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. Obstet Gynecol; 2005 May;105(5 Pt 2):1278-80
Hazardous Substances Data Bank. RALOXIFENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.
  • BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer.
  • We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.
  • CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.
  • Diagnosis had been delayed secondary to sampling of the other uterine horn.
  • CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.
  • Special attention should be paid when attempting to sample the endometrium in patients with mullerian abnormalities.
  • [MeSH-major] Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / pathology. Raloxifene Hydrochloride / adverse effects. Selective Estrogen Receptor Modulators / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Middle Aged. Neoplasm Staging. Osteoporosis, Postmenopausal / diagnosis. Osteoporosis, Postmenopausal / drug therapy. Ovariectomy / methods. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863610.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 4F86W47BR6 / Raloxifene Hydrochloride
  •  go-up   go-down


14. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C: A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol; 2007 May;105(2):399-403
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
  • PURPOSE: To evaluate the efficacy and toxicity of cisplatin and ifosfamide in the treatment of patients with malignant mixed mesodermal tumor (MMMT) of the ovary.
  • METHODS: Ten patients with histologically confirmed primary MMMT of the ovary diagnosed between 1993 and 2001 were enrolled in the study.
  • Treatment consisted of cisplatin 75 mg/m2 on day 1, followed by ifosfamide 2.0 g/m2 over 24 h on days 1, 2 and 3.
  • Chemotherapy was repeated on a 28-day cycle if blood counts permitted.
  • RESULTS: Eight of the nine patients responded to therapy, with 7 complete responses (78%) and 1 partial response.
  • One patient remained free of disease 94.4 months after diagnosis, and one patient remained alive with recurrence 125.5 months following diagnosis.
  • CONCLUSION: The combination of cisplatin and ifosfamide/mesna demonstrated activity against MMMT of the ovary.
  • Novel agents with activity against MMMT of the ovary and acceptable toxicity are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mesodermal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Mesna / administration & dosage. Mesna / adverse effects. Middle Aged. Neoplasm Staging. Pilot Projects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292457.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Gagner JP, Mittal K: Malignant mixed Mullerian tumor of the fimbriated end of the fallopian tube: origin as an intraepithelial carcinoma. Gynecol Oncol; 2005 Apr;97(1):219-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumor of the fimbriated end of the fallopian tube: origin as an intraepithelial carcinoma.
  • BACKGROUND: A paucity of examples of malignant mixed Mullerian tumors (MMMT) of the fimbriated end of the fallopian tube has been reported.
  • CASE: We report a first case of FIGO Stage IV primary MMMT, heterologous type, in the right fimbria of a 77-year-old woman associated with symptomatic pleural spread who succumbed with recurrent disease 12 months after resection and postoperative paclitaxel and carboplatin chemotherapy.
  • CONCLUSIONS: The identification of intraepithelial carcinoma in this tumor lends support to a role of the epithelial component in fimbrial MMMT histogenesis as seen for MMMT at other anatomic sites.
  • Comparison of the clinical management of these tumors shows prolonged survival of patients whose treatment included postoperative pelvic external radiotherapy.
  • [MeSH-major] Carcinoma in Situ / pathology. Fallopian Tube Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790462.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


16. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, DeGeest K, Miller BE, Susumu N, Ueland FR: A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study. J Clin Oncol; 2009 May 20;27(15_suppl):5515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study.
  • : 5515 Background: Both platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor).
  • METHODS: Eligible patients had advanced stage (III or IV), persistent, or recurrent measurable disease with histologic confirmation of the primary tumor, no prior chemotherapy, and a GOG Performance Status of 2 or better.
  • Patients received the combination of paclitaxel 175 mg/m2 IV over 3 hours plus carboplatin (AUC 6) IV over 30 minutes every 3 weeks until disease progression or adverse effects prohibit further therapy.
  • This study used an optimal but flexible two-stage design with early stopping guidelines intended to limit patient accrual to inactive treatments.
  • RESULTS: Fifty-five patients were entered on study with 9 being excluded from analysis; 7 with unconfirmed diagnosis at CPR and 2 were never treated.
  • Treatment was generally tolerated with expected hematologic toxicity and minimal non-hematologic grade 4 toxicity (1 cardiovascular and 2 pain) with 59% of patients completing 6 or more cycles of chemotherapy.
  • Additionally 4% experienced an unconfirmed response and 26% had stable disease.
  • CONCLUSIONS: Paclitaxel plus carboplatin demonstrates anti-tumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962461.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, Edwards RP: Chemotherapy for malignant mixed Müllerian tumors of the ovary. Gynecol Oncol; 2000 Nov;79(2):196-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for malignant mixed Müllerian tumors of the ovary.
  • OBJECTIVE: The aim of this study was to review the chemotherapy experience at Magee-Womens Hospital for malignant mixed müllerian tumor (MMMT) of the ovary.
  • Patients were treated with either paclitaxel/carboplatin (PC) outpatient chemotherapy or platinum/ifosfamide (PI) inpatient chemotherapy as first- or second-line therapy.
  • METHODS: Thirteen patients diagnosed with MMMT of the ovary after complete surgical staging from 1990 to 1999 were studied retrospectively.
  • Six patients received PC combination chemotherapy, of which 3 patients received PC as first-line treatment.
  • The other 3 patients received PC as second-line therapy.
  • Demographic data, pathology, cytoreductive surgery, treatment, and survival rates were reviewed.
  • Complete clinical response (CR) was defined as the disappearance of all measurable disease or normalization of elevated CA 125 level after chemotherapy.
  • RESULTS: The median survival time of patients receiving PC was 19 months.
  • One patient, after receiving PC as first-line treatment, demonstrated a CR and is free of disease beyond 33 months.
  • The median survival time of patients managed with PI was 23 months.
  • Three patients with suboptimal disease demonstrated CR after receiving PI.
  • CONCLUSIONS: Optimal chemotherapy regimen for MMMT of ovary remains to be determined.
  • Platinum-based chemotherapy in combination with ifosfamide or paclitaxel may be active against this rare malignancy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Platinum / administration & dosage. Platinum / adverse effects. Retrospective Studies. Survival Analysis. Taxoids. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11063643.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Taxoids; 49DFR088MY / Platinum; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide; PC protocol; PI protocol
  •  go-up   go-down


18. Ulbricht LJ, Kunert M, Gremmler B, Evagelopoulos N, Krian A, Moege J: Intracardiac metastasis of a Malignant Mixed Mullerian tumor (MMMT): progressive dyspnoea due to obstruction of the left atrium and the left ventricle without left ventricular dysfunction or primary lung disease. Wien Med Wochenschr; 2009;159(13-14):355-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracardiac metastasis of a Malignant Mixed Mullerian tumor (MMMT): progressive dyspnoea due to obstruction of the left atrium and the left ventricle without left ventricular dysfunction or primary lung disease.
  • Malignant Mixed Mullerian tumors (MMMT) are rare gynecological tumors.
  • Even with surgical treatment, chemotherapy, and/or radiotherapy, outcome is poor.
  • In a 61-year-old female patient who had undergone surgical resection of a Mullerian tumor of the uterus 26 months prior to being admitted to our department, we found an obstructing left atrial mass.
  • Histopathologic assessment of this lesion after surgical resection revealed a Mullerian tumor metastasis.
  • On a literature review, we did not find any description of left atrial and left ventricular occluding metastases of MMMT.
  • [MeSH-major] Dyspnea / etiology. Heart Atria. Heart Neoplasms / diagnosis. Heart Ventricles. Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / secondary. Uterine Neoplasms / diagnosis. Ventricular Function, Left / physiology
  • [MeSH-minor] Disease Progression. Echocardiography. Echocardiography, Transesophageal. Female. Humans. Middle Aged. Palliative Care. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2005;44(7):756-60 [16227168.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):303-7 [9740711.001]
  • [Cites] Gynecol Obstet Invest. 1997;44(3):214-6 [9359652.001]
  • [Cites] Gynecol Oncol. 1991 Nov;43(2):186-90 [1660435.001]
  • [Cites] Int Surg. 1989 Jul-Sep;74(3):195-7 [2558083.001]
  • [Cites] Breast J. 2002 Sep-Oct;8(5):305-6 [12199759.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):155-9 [3000571.001]
  • [Cites] Am J Surg Pathol. 1979 Apr;3(2):125-35 [231382.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):422-6 [2839396.001]
  • [Cites] Acta Obstet Gynecol Scand. 1986;65(7):811-2 [3811858.001]
  • [Cites] Singapore Med J. 2002 Sep;43(9):452-6 [12568422.001]
  • [Cites] JOP. 2006 Jan 11;7(1):66-9 [16407622.001]
  • (PMID = 19652943.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


19. Topuz E, Eralp Y, Aydiner A, Saip P, Taş F, Yavuz E, Salihoğlu Y: The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract. Eur J Gynaecol Oncol; 2001;22(6):469-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.
  • Thirteen patients with malignant mixed mullerian tumor of the female genital tract, treated and followed in our clinic from 1989 to 1999 were retrospectively evaluated.
  • Seven patients (53.8%) with advanced disease or postoperative residual tumor were treated with adjuvant chemotherapy.
  • The median age at diagnosis was 64 years (range: 26-79).
  • Tumors were localized to the endometrium in five (62.5%), to the ovaries in two (25%) and to the fallopian tube in one (12.5%) patient.
  • Six patients received cisplatinum-based chemotherapy (4 had doxorubicin including combinations), while one patient was treated with a doxorubicin+ifosphamide combination.
  • Five patients (71.4%) had a complete response (CR) to chemotherapy.
  • Response duration in patients with a CR was +13, +67, +10, +14 and +2 months, respectively.
  • After a median follow-up period of 20 months (3-115 months), six patients have died, five are being followed-up with no evidence of disease, one is alive with metastatic disease and one patient is under treatment.
  • Malignant mixed mullerian tumor of the female genital tract is highly responsive to multimodality treatment strategies.
  • Further prospective studies are required to identify distinct prognostic groups that may benefit from various treatment modalities.
  • [MeSH-major] Genital Neoplasms, Female / drug therapy. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874086.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF: Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol; 2002 Jun;85(3):459-63
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary.
  • OBJECTIVE: Malignant mixed müllerian tumor (MMMT) of the ovary is a rare tumor with a dismal prognosis.
  • The most effective therapy is unknown.
  • The current study was undertaken to characterize a group of patients treated as if they had aggressive epithelial ovarian tumors, with cytoreductive surgery and combination paclitaxel/platinum chemotherapy.
  • METHODS: Retrospective analysis of data obtained from tumor registry and hospital records of cases of malignant mixed müllerian tumor between January 1, 1992 and January 1, 2000 treated at the Massachusetts General Hospital, Brigham and Women's Hospital, and University of Vermont was performed.
  • Only patients treated with combination paclitaxel and platinum therapy were included in the analysis.
  • Data were collected regarding cytoreduction, response to chemotherapy, disease-free interval, and survival.
  • RESULTS: Fifty-five patients were identified with MMMT.
  • Twenty-eight patients with a clearly ovarian primary had received treatment with combination paclitaxel and platinum.
  • Paclitaxel and carboplatin was given as second-line therapy in 2 patients who had chemoresponsive but incurable disease; the remaining patients were treated with paclitaxel and platinum therapy as first-line therapy.
  • Treatment was generally well tolerated.
  • Sixteen patients of 26 treated with paclitaxel and platinum as first-line therapy achieved a complete clinical response (55%) and 6 patients achieved partial response for a total response rate of 72%.
  • Optimal cytoreduction was associated with increased time to recurrence (P = 0.001) but not with survival.
  • CONCLUSION: Although treatment fails many patients, a minority of patients with MMMT in this highly selected population do unexpectedly well.
  • An aggressive approach with surgery and combination paclitaxel-platinum chemotherapy appears to offer very effective therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12051874.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH: Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):101-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy.
  • This study reviews the clinical outcome and prognosis of patients with malignant mixed müllerian tumors (MMMTs) of the ovary treated with optimal cytoreductive surgery, leaving no residual disease, and platinum-based chemotherapy.
  • Ten patients diagnosed with MMMT of the ovary after complete surgical staging from February 1993 to February 2004 at Asan Medical Center in Korea were studied retrospectively.
  • All ten patients were treated with optimal cytoreductive surgery, leaving no gross residual disease.
  • Seven patients received ifosfamide/cisplatin chemotherapy, and the remaining three patients received other platinum-based combination chemotherapy.
  • Demographic data, pathologic findings, treatments, and survival time were reviewed.
  • The median survival time of all ten patients was 46 months.
  • Platinum-based combination chemotherapy after optimal cytoreductive surgery may be effective in the treatment of ovarian MMMT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / mortality. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Probability. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


22. Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N: Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube. Int J Clin Oncol; 2008 Oct;13(5):461-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube.
  • Malignant mixed müllerian tumors (MMMT) of the fallopian tube are extremely rare, and optimal therapy for them is unknown.
  • Pathological examination determined International Federation of Gynecology and Obstetrics (FIGO) stage IIIc MMMT of the right fallopian tube.
  • The patient received three courses of chemotherapy, consisting of 175 mg/m(2) paclitaxel and AUC=5 carboplatin (TC therapy), administered at 3-week intervals.
  • The tumor attached to the sigmoid colon had shrunk by 60% after chemotherapy.
  • The patient received an additional five courses of adjuvant TC therapy.
  • The patient is alive and free of disease 28 months after the debulking surgery.
  • TC therapy may be effective for MMMT of the fallopian tube.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Mixed Tumor, Mullerian / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Ovariectomy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):114-24 [1330846.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):101-5 [16445618.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):219-22 [15790462.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(1):47-53 [8789433.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jul-Aug;14(4):690-3 [15304169.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):187-92 [8380115.001]
  • [Cites] Gynecol Oncol. 1984 Jul;18(3):278-92 [6086467.001]
  • [Cites] Acta Obstet Gynecol Scand. 1994 Apr;73(4):352-4 [8160547.001]
  • [Cites] Int J Gynecol Cancer. 1999 Jul;9(4):312-316 [11240785.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 1):735-9 [7724104.001]
  • (PMID = 18946759.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC: Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. Acta Oncol; 2005;44(7):756-60
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature.
  • Malignant mixed mullerian tumors (MMMTs), also known as carcinosarcoma because they contain both carcinomatous and sarcomatous elements are aggressive tumors, which usually arise in the uterus and ovary.
  • Here we report a case of a primary carcinosarcoma of the pelvic peritoneum with five-year disease-free survival after managing the patient with surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Carcinosarcoma / diagnosis. Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Mullerian / diagnosis. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Laparotomy. Middle Aged. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227168.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Inthasorn P, Beale P, Dalrymple C, Carter J: Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol; 2003 Feb;43(1):61-4
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy.
  • OBJECTIVES: The purpose of the present study was to analyse retrospectively the data of a series of patients presenting to our unit with malignant mixed mullerian tumour (MMMT) of the ovary to identify the prognostic factors and relate them to survival.
  • The role of platinum-based chemotherapy in the adjuvant treatment of this tumour was also evaluated.
  • METHODS: All patients diagnosed with MMMT of the ovary from 1987 to 2000 were identified from the gynaecological tumour registry of King George V Hospital, Australia.
  • The response of platinum-based adjuvant chemotherapy after surgery was also evaluated.
  • RESULTS: Twenty patients with MMMT of the ovary were identified.
  • Of the six patients with measurable disease, two (33%) had complete response after adjuvant platinum-based chemotherapy.
  • The median survival of all patients was 8 months, while that of the patients receiving adjuvant platinum-based chemotherapy was 23 months.
  • CONCLUSIONS: Malignant mixed mullerian tumour of the ovary is a rare and aggressive gynaecological tumour.
  • The current study indicates that patient age was a significant prognostic factor for survival and surgical cytoreduction combined with platinum-based chemotherapy is the most effective management regimen identified to date to treat MMMT of the ovary.
  • [MeSH-major] Mixed Tumor, Mullerian / therapy. Ovarian Neoplasms / therapy. Platinum Compounds / therapeutic use
  • [MeSH-minor] Age Factors. Aged. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Ovariectomy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12755351.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Platinum Compounds
  •  go-up   go-down


25. Zhang C, Cui H, Zhao Y, Liang XD, Wang CH, Li XP, Shen DH, Wang SJ, Wei LH: [Clinical management and prognostic analysis of primary peritoneal neoplasms]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jul;40(7):464-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 24 cases, 15 patients were diagnosed as serous papillary adenocarcinoma (9 highly and intermediately differentiated, and 6 lowly differentiated), 6 as mixed epithelial carcinoma and 3 as mixed malignant Mullerian tumor (MMMT).
  • Then they received a platinum-based chemotherapy.
  • Thirteen cases received paclitaxel + cisplatin (TP) and 9 received cisplatin + doxorubicin + cyclophosphamide (PAC) combination chemotherapy.
  • Survival for patients with primary peritoneal serous papillary carcinoma (PPSPC), mixed epithelial carcinoma and MMMT was 44, 19 and 13 months respectively, with a significant difference between PPSPC and MMMT (P < 0.05).
  • TP combination therapy may bring longer survival than PAC regimen.
  • Histopathologic types and chemotherapy regimens are the essential factors of the prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080873.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Fotiou S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N: Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res; 2000 May-Jun;20(3B):2015-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature.
  • Two cases of uterine carcinosarcoma developing after long-term tamoxifen (TAM) treatment are presented.
  • They both developed an heterologous malignant mixed Mullerian tumor (mmMt).
  • At laparotomy, an advanced stage of disease was found with peritoneal spread.
  • In spite of the surgical and the postoperative treatment, they both died of disease, 3 and 10 months later.
  • Another 7 were identified in series of uterine malignancies developing after TAM treatment.
  • Considerable evidence suggests that mmMt represents an epithelial cancer with sarcomatous dedifferentiation.
  • Prolonged (> 5 years) TAM treatment may represent a causative factor in the development of this highly lethal disease (80% of the reported patients had a dismal prognosis).
  • Large uterine polyps with special histological features, may represent an intermediate step in the tumor formation.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Carcinosarcoma / chemically induced. Mixed Tumor, Mullerian / chemically induced. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Mastectomy. Methotrexate / administration & dosage. Ovariectomy. Peritoneal Neoplasms / secondary. Polyps / chemically induced

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10928144.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  • [Number-of-references] 42
  •  go-up   go-down


27. Fowler JM, Blessing JA, Burger RA, Malfetano JH: Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. Gynecol Oncol; 2002 May;85(2):311-4
Hazardous Substances Data Bank. TRIMETREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
  • OBJECTIVES: This is a Phase II group-wide study of the Gynecologic Oncology Group to determine the toxicity and objective response rate of trimetrexate (TMTX) in patients with advanced, persistent, or recurrent mixed mesodermal tumors of the uterus who have failed higher priority treatment protocols.
  • The minimum treatment period was one course.
  • Patients who had a complete response, partial response, or stable disease were continued on treatment for at least three courses.
  • Twenty-five patients were evaluable for toxicity, and 21 were evaluable for response, as 4 patients did not complete one course of therapy.
  • Eleven patients had heterologous mixed mesodermal tumor (MMT) and 10 had homologous MMT.
  • CONCLUSION: Oral TMTX has insignificant activity in the treatment of advanced, persistent, and recurrent uterine MMT at the dose and schedule administered.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Mixed Tumor, Mesodermal / drug therapy. Trimetrexate / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2002 Elsevier Science (USA).
  • (PMID = 11972393.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; UPN4ITI8T4 / Trimetrexate
  •  go-up   go-down


31. Dede M, Gezginç K, Alanbay I, Fidan U, Yenen M: A sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma: a case report. Eur J Gynaecol Oncol; 2008;29(2):193-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma: a case report.
  • A rare case of a patient with a histopathological diagnosis of a sarcomatous-type peritoneal malign mixed müllerian tumor implant in association with ovarian adenocarcinoma is reported.
  • At laboratory examination tumor marker CA-125 was 280.4 U/ml (< 35), CA-15-3 was 146.5 U/ml (< 25), whereas other markers were within normal range.
  • A staging laparatomy procedure was applied.
  • Postoperative histopathological diagnosis was reported as malignant mixed mullerian tumor of the ovary, with the ovarian component as poorly differentiated adenocarcinoma, and the metastatic foci over serosal surfaces as a sarcomatous component.
  • Postoperatively six courses of adjuvant and consolidation chemotherapy were administered to the patient.
  • Further studies are needed to set a consensus about evaluation of treatment and prognosis for this kind of pathology.
  • [MeSH-major] Adenocarcinoma / complications. Mixed Tumor, Mullerian / complications. Ovarian Neoplasms / complications. Peritoneal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459565.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Gari A, Souhami L, Arseneau J, Stanimir G: Primary malignant mesodermal ovarian sarcomas. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):106-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesodermal ovarian sarcomas.
  • Primary malignant mesodermal ovarian sarcomas are rare tumors and have a poor prognosis.
  • The disease is usually diagnosed at a late stage and 5-year survivals are uncommon.
  • Most patients are treated with debulking surgery followed by adjuvant chemotherapy.
  • All patients underwent surgery and 90% received adjuvant chemotherapy.
  • Newer treatment strategies are urgently needed in the management of this disease.
  • [MeSH-major] Cause of Death. Mixed Tumor, Mesodermal / mortality. Mixed Tumor, Mesodermal / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Prognosis. Risk Assessment. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445619.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Dören M, Rydh W, Rudenstam G, Granberg S: The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet; 2000 Apr;263(4):170-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We restudied histologically and immunohistochemically 17 endometrial carcinomas, 2 malignant mixed tumors and 180 endometria with benign changes during or after tamoxifen therapy.
  • None of 11 patients biopsied before starting tamoxifen therapy had advanced endometrial glandular proliferation in the second endometrial biopsy after tamoxifen treatment.
  • None of the 19 endometrial neoplasms after tamoxifen therapy was of the endometrioid type: 11 were mucinous adenocarcinomas, 4 clear cell carcinomas, 2 serous-papillary carcinomas, one carcinosarcoma and one malignant Mullerian mixed tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrium / drug effects. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy. Carcinosarcoma / chemically induced. Carcinosarcoma / pathology. Carcinosarcoma / ultrasonography. Cystadenocarcinoma, Papillary / chemically induced. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / ultrasonography. Female. Humans. Immunohistochemistry. Middle Aged. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / ultrasonography. Polyps. Retrospective Studies. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834325.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


34. Kanjeekal S, Chambers A, Fung MF, Verma S: Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol; 2005 May;97(2):624-37
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.
  • OBJECTIVE: To conduct a systematic review of the literature regarding the systemic treatment of advanced uterine sarcoma and provide an evidence-based summary of the available literature.
  • "Uterine sarcoma," "leiomyosarcoma," "mixed mesodermal tumor," "chemotherapy," and "systemic therapy" were combined with the search terms for study designs.
  • In a randomized trial of doxorubicin versus doxorubicin plus cyclophosphamide for advanced or recurrent uterine sarcoma, doxorubicin produced an overall response rate (RR) of 19% and median survival of 11.6 months, which was similar to the response with combination chemotherapy (RR 19%, median survival 10.9 months).
  • A randomized trial comparing ifosfamide plus cisplatin versus ifosfamide alone in mixed mesodermal tumors showed a significant improvement in RR and progression-free survival with the combination compared with ifosfamide alone, however, the combination was associated with increased toxicity including death.
  • CONCLUSIONS: Offering palliative chemotherapy to patients with advanced, unresectable uterine sarcoma who are symptomatic from this disease is a reasonable decision.
  • The combination of cisplatinum and ifosfamide is also an option for women with metastatic mixed mesodermal tumors; however, this combination is associated with significant toxicity when compared to ifosfamide alone.
  • [MeSH-major] Mixed Tumor, Mesodermal / drug therapy. Sarcoma, Endometrial Stromal / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Female. Humans. Leiomyosarcoma / drug therapy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863170.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


35. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • The resected tumor measuring over 20 cm in diameter consisted of cystic and solid components and was very fragile.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • There was no tumor immunoreactivity to alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and inhibin.
  • In spite of aggressive combination chemotherapy and three times of laparotomy, the patient died of disease 3 years 10 months after the initial treatment.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


36. Liao Q, Wang J, Han J: [Clinical and pathological analysis on 106 cases with uterine sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2001 Feb;36(2):104-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the clinical features and factors affecting the prognosis of uterine sarcoma with different histological types.
  • METHODS: One hundred and six cases with uterine sarcoma treated were analyzed retrospectively, among which there were 67 cases with leiomyosarcoma (63.2%), 23 with malignant endometrial interstitial sarcomas (21.7%), 16 with malignant Mullerian mixed tumor (15.1%).
  • The patients usually manifested with abnormal vaginal bleeding (67.0%), palpable mass of lower abdomen (32.1%), vaginal discharge (27.4%), pain on lower abdomen (28.4%), symptoms of oppression (25.5%), and discomfort feeling (28.3%). (2) The rate of preoperative diagnosis was 65.9%, especially that of leiomyosarcoma was lowest (42.9%). (3) In treatment, 16.0% of patients was treated by hysterectomy; bilateral salpingo-oophorectomy and pelvic lymphadenectomy; 75.5% of them by hysterectomy and bilateral salpingo-oophorectomy; after operation, 74.5% of them were treated by chemotherapy, 11.3% by radiotherapy, 6.6% by additional progesterone. (4) The survival period of the patients was related to pathologic types and clinical stages and ages of the patients.
  • The patients with leiomyosarcoma are younger and have better prognosis, but the rate of preoperative diagnosis is low.
  • The prognosis of uterine sarcoma is related to pathologic types, clinical stage and ages of the patients.

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783345.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Ferrandina G, Zannoni GF, Martinelli E, Vellone V, Prisco MG, Scambia G: Endometrial carcinoma recurring as carcinosarcoma: report of two cases. Pathol Res Pract; 2007;203(9):677-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial carcinosarcoma is a rare, aggressive disease, accounting for approximately 3% of all uterine neoplasms.
  • Case 1. a 58-year-old postmenopausal woman diagnosed to have a poorly differentiated endometrial endometrioid adenocarcinoma (FIGO stage IB) developed an intra-abdominal recurrence of disease after 17 months from diagnosis.
  • Salvage chemotherapy with cisplatin, ifosfamide, epirubicin, and then with taxotere was attempted.
  • A 56-year-old woman with a diagnosis of grade 3 endometrial adenosquamous carcinoma of the endometrium (FIGO stage IIIA) experienced pelvic recurrence after five months from completion of chemotherapy.
  • Definitive histology was malignant mixed mesodermal tumor with focal areas of chondrosarcomatous elements.
  • The patient was triaged to exclusive concomitant chemoradiotherapy and salvage chemotherapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Chondrosarcoma / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646054.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


38. Aygun B, Kimpo M, Lee T, Valderrama E, Leonidas J, Karayalcin G: An adolescent with ovarian osteosarcoma arising in a cystic teratoma. J Pediatr Hematol Oncol; 2003 May;25(5):410-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 14-year-old girl had an abdominal mass with the characteristics of an ovarian germ cell tumor on computed tomography scan.
  • Seven months after completion of chemotherapy, there were simultaneous local recurrence and lung metastases.
  • Previously, 10 cases of ovarian osteosarcoma have been reported in the literature: 5 were primary osteosarcoma of the ovary, 4 were associated with teratomas, and 1 was part of a malignant mixed mesodermal tumor of the ovary.
  • Of the 10, there are only 2 long-term survivors, both of whom were treated with adjuvant chemotherapy following complete resection.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12759630.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


39. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ: Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1243-8
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole.
  • Uterine malignant mixed müllerian tumor (MMMT) is a rare malignancy occurring most often in postmenopausal women.
  • Despite the use of multimodality treatments including surgery, chemotherapy, and radiotherapy, prognosis is still poor in most cases.
  • We report the case of a 69-year-old woman with recurrent metastatic high-grade MMMT that responded to letrozole, an aromatase inhibitor.
  • At the initial diagnosis of high-grade uterine MMMT in February 2001, the patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and postoperative pelvic radiotherapy.
  • Two years later, an asymptomatic retroperitoneal mass was discovered on surveillance abdominal computed tomography scanning.
  • The patient declined radiation or chemotherapy.
  • Treatment with letrozole was begun at 2.5 mg daily.
  • Serial computed tomography scans demonstrated marked tumor shrinkage; after 11 months of letrozole therapy, the tumor had shrunk to less than 25% of its original volume.
  • Further study of letrozole for high-grade uterine MMMT is warranted.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343224.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


40. Viereck V, Huschmand Nia A, Pauer HU, Emons G, Krauss T: [Diagnosis and therapy of uterine sarcoma]. Zentralbl Gynakol; 2002 Nov;124(11):506-10
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of uterine sarcoma].
  • [Transliterated title] Diagnostik und Therapie der Uterussarkome.
  • Radical surgery in stage I and II uterine sarcoma removing all tumor manifestations is the only curative therapy option for early stage disease.
  • Larger tumors (> 4 cm) and the presence of lymph node metastasis correlate with a high local recurrence rate.
  • For these tumors adjuvant radiation and/or adjuvant chemotherapy may be recommended after surgical therapy.
  • Adjuvant therapy however, should preferably be considered for uterine stromal sarcomas and mixed mesodermal tumors.
  • The toxicity of radiation and/or chemotherapy is greater than any possible benefit for patients with leiomysarcomas as these tumors rarely respond to radiation or chemotherapy.
  • For advanced (> stage I and II) and recurrent disease, curative therapy options are not available and palliative therapy for these patients has to take into consideration the negative side effects and weigh up quality of life against an often very limited possible benefit of such therapy.
  • [MeSH-major] Sarcoma / diagnosis. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796843.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


41. Hsieh CL, Chang TC, Lai CH, Jung SM, Chou HH: Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review. Gynecol Oncol; 2004 Sep;94(3):854-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review.
  • INTRODUCTION: Ovarian malignant mixed müllerian tumor (MMMT) is a rare, highly aggressive, fatal disease.
  • Optimal cytoreduction surgery plus platinum-based combination chemotherapy are associated with better outcomes.
  • CASE REPORT: A 65-year-old patient of stage IIIc ovarian MMMT having obtained a 41-month remission after four courses of aggressive surgical debulking procedures, platinum-containing chemotherapy, and intraoperative radiotherapy suffered from multi-focal recurrences and obtained another 22-month progression-free survival after treatment with monthly liposomal doxorubicin (Lipo-Dox) for 14 courses and Lipo-Dox/carboplatin for subsequent 6 courses without obvious toxicity.
  • DISCUSSION: Liposomal doxorubicin might be useful as salvage chemotherapy for heavily pretreated, recurrent ovarian MMMT.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15350389.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin
  • [Number-of-references] 10
  •  go-up   go-down


42. Müller H, Nakchbandi V: Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. Eur J Surg Oncol; 2004 Jun;30(5):573-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
  • BACKGROUND: Malignant mixed mesodermal tumours (MMMT) of the female genital tract are rare and heterogeneous malignancies that impart grim prognosis.
  • These tumours are characterized by an admixture of malignant epithelial and stromal elements comprising carcinomatous and sarcomatous neoplastic cells.
  • Thus far, almost 350 cases of MMMT have been recorded in the international medical literature.
  • Due to its rarity, there is no agreement on the best treatment strategy in women with metastasized MMMT.
  • METHODS: Six women (mean age 59 years) with metastasized MMMT defined to the peritoneal cavity have been treated by cytoreductive surgery plus hyperthermic peritoneal perfusion plus postoperative adjuvant chemotherapy.
  • All patients have been pre-treated by surgery for primary tumour and one by systemic chemotherapy.
  • As adjuvant treatment CDDP 40 mg/m2/dl, Mitomycin 7 mg/md2/dl and Ifosfamid 100 mg/kg 24 h/dl was applicated via intraaortic catheter three times with a treatment free interval of 3 weeks.
  • RESULTS: A complete cytoreduction without remnant tumour formations in the peritoneal cavity could be carried out in all six patients.
  • One patient died 4 months later by pneumonia without evidence of disease.
  • Four patients are without evidence of disease after 2, 4, 14 and 19 months, whereas one patient developed liver metastases after 9 months still treated by systemic chemotherapy.
  • CONCLUSION: Complete cytoreduction plus hyperthermic peritoneal perfusion plus adjuvant chemotherapy seems to be an effective treatment for recurrent or metastasized MMMT.
  • Further studies have to define the value of this new treatment strategy for this rare tumour entity.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mixed Tumor, Malignant / secondary. Mixed Tumor, Malignant / therapy. Mixed Tumor, Mesodermal / secondary. Mixed Tumor, Mesodermal / therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Germany. Humans. Ifosfamide / administration & dosage. Laparotomy. Liver / pathology. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Peritoneal Cavity / pathology. Treatment Outcome. Women's Health

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2005 Feb;31(1):111-2 [15642436.001]
  • (PMID = 15135489.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 50SG953SK6 / Mitomycin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


43. Lenhard SM, Untch M, Himsl I, Ditsch N, Bittmann I, Friese K, Bauerfeind I: The high-grade endometrial sarcoma: a rare entity. Arch Gynecol Obstet; 2006 Apr;274(1):56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: With an estimated incidence of one to two per one million women, the endometrial stromal sarcoma (ESS) is a rare disease.
  • It is subclassified into a high-grade and a prognostically better low-grade type.
  • Evidence-based data for a standardized therapy is lacking.
  • A fractioned curettage yielded a differential diagnosis of malignant muellerian mixed tumor or a non-differentiated endometrial sarcoma.
  • For completion of the operative treatment, laparotomy with hysterectomy, adnexectomy, and pelvine lymphonodectomy were performed.
  • The final histological report described a 7 cm non-differentiated endometrial sarcoma with infiltration of the left ovary and 25 tumor-free lymph nodes.
  • DISCUSSION: Standard therapy for resectable sarcoma is abdominal hysterectomy and bilateral adnexectomy.
  • So far, there is little data from studies reporting radio- or chemotherapy treatment of small patient numbers in an adjuvant setting.
  • CONCLUSION: The ESS is a very rare disease of the uterus.
  • Due to missing clinical data, it remains a multidisciplinary therapeutic challenge requiring individual decisions.
  • To receive more information on this rare disease, treatment should be performed according to international protocols.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Hysterectomy. Metrorrhagia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311750.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Ozguroglu M, Bilici A, Ilvan S, Turna H, Atalay B, Mandel N, Sahinler I: Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):809-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it?
  • Malignant mixed müllerian tumors (MMMT) are highly aggressive tumors, usually diagnosed in advanced stage.
  • Cases of MMMT derive from either ovary or uterus.
  • In our study, we investigated the role of carcinomatous and sarcomatous component on response to chemotherapy and disease outcome.
  • We retrospectively analyzed 25 patients with MMMT who were treated in our outpatient clinic from 1998 to 2003.
  • All the paraffin specimens were reevaluated according to the histopathologic features (primary site and percentages of carcinomatous and sarcomatous component) and the effect of predominant histologic type on response to treatment.
  • Primary tumor sites were ovary and endometrium in 36% and 64% of patients, respectively.
  • Ten of 25 patients (40%) were treated with a combination chemotherapy regimen of cisplatin-ifosfamide (PI) and 7 patients (28%) were treated with paclitaxel-carboplatin (PC) protocol.
  • Despite chemotherapy, 17.6% of patients had progressive disease.
  • The remaining 13 patients (54.2%) responded to chemotherapy.
  • MMMT are highly chemoresponsive tumors, irrespective of primary site.
  • Predominating histopathologic feature (carcinoma or sarcoma) should be taken into consideration in predicting the response and planning the chemotherapy regimen.
  • [MeSH-major] Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Planning Techniques. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892455.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Rebischung C, Pautier P, Morice P, Lhomme C, Duvillard P: Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary. Gynecol Oncol; 2000 Apr;77(1):203-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary.
  • Elevated levels of alpha-fetoprotein (AFP), a fetal serum protein, usually signal the development of hepatoma or germ cell tumors, including endodermal sinus tumors.
  • We report the case of a 52-year-old woman with an alpha-fetoprotein-producing malignant mixed Müllerian tumor (MMMT) of the ovary.
  • Serum AFP was 5348 ng/ml at diagnosis.
  • Immunohistochemistry confirmed that the carcinomatous component of this biphasic tumor was the seat of AFP production.
  • After three cycles of combination chemotherapy, the patient achieved a complete remission.
  • Serum AFP was strongly correlated with response to treatment.
  • This is the first report of AFP production by a MMMT of the ovary without a yolk sac component.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Mixed Tumor, Mullerian / metabolism. Ovarian Neoplasms / metabolism. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10739713.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


46. Shen YM, Xie YP, Xu L, Yang KX, Yu N, Yu Y, Wang JH: Malignant mixed müllerian tumor of the fallopian tube: report of two cases and review of literature. Arch Gynecol Obstet; 2010 Jun;281(6):1023-8
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of the fallopian tube: report of two cases and review of literature.
  • PURPOSE: Malignant mixed müllerian tumors (MMMT) of the female genital tract is rare and it is extremely rare in the fallopian tube, with fewer than 53 cases reported in the literature.
  • METHODS: We had experienced two cases of MMMT of the fallopian tube.
  • The clinical features, pathologic findings, diagnosis, therapy, and outcome were reviewed.
  • RESULTS: The clinical features and diagnosis were similar to those of primary carcinoma of the fallopian tube.
  • Histologically, the two patients had homologous and heterologous elements mixed müllerian tumors.
  • Treatment has focused on surgery with postoperative chemotherapy.
  • CONCLUSIONS: MMMT of fallopian tube is an uncommon carcinoma in the female genital tract.
  • Cervical cytology and endometrial curettage could raise the suspicion of a tubal malignancy, but diagnosis is not usually made until the time of surgery.
  • The patient survival will improve after surgery and postoperative chemotherapy.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Fallopian Tube Neoplasms / therapy. Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033419.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 18
  •  go-up   go-down


47. Ma CJ, Yang SF, Huang CC, Chai CY, Cheng KI, Tsai EM, Wang JY: Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review. Eur J Gynaecol Oncol; 2008;29(3):289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review.
  • Malignant mixed müllerian tumor (MMMT) is a rare tumor in females and extragenital MMMT is even more so.
  • We report a patient with MMMT primarily in the mesentery with synchronous ovarian cancer.
  • In the English literature, 42 cases of extragenital MMMT have been reported other than the presented case, and this is only the second MMMT arising from the mesentery.
  • Furthermore, among the cases reviewed, MMMTs tend to be associated with synchronous or metachronous colonic cancer or gynecologic tumors originating from the müllerian duct, including ovarian tumors, fallopian tube cancer, endometrial cancer, cervical cancer, and serous carcinoma of the peritoneum (14 out of 43 patients; 32.6%).
  • The risk factors for MMMT include obesity, nulliparity, exogenous estrogen, and long-term tamoxifen use.
  • The prognosis of MMMT is catastrophic and the treatment is based on the experience of those of uterine sarcomas, which is composed of operation, radiotherapy and chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Mesentery / pathology. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Middle Aged. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Postmenopause


48. Curtin JP, Blessing JA, Soper JT, DeGeest K: Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol; 2001 Nov;83(2):268-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
  • OBJECTIVE: The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments.
  • METHODS: The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m(2) (135 mg/m(2) in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy.
  • Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors.
  • Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11606082.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


49. Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, Tinker AV, British Columbia Cancer Agency: Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol; 2008 Jan;108(1):58-62
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
  • OBJECTIVES: Uterine MMMTs are aggressive malignancies that are rarely cured by purely local therapies.
  • Effective chemotherapy is needed.
  • Carboplatin and paclitaxel (CT) are easy to deliver and is effective against endometrial carcinoma and should be against MMMT (as they are now regarded as epithelial in nature).
  • METHODS: A review of all women with uterine MMMT treated with CT.
  • Dose reduction occurred in 5%, treatment delay in 10%.
  • CONCLUSIONS: Carboplatin-paclitaxel is effective against uterine MMMT, with similar efficacy to ifosfamide combinations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17935761.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


50. Wei CF, Hwang SH, Ho CM, Shih BY, Chien TY: Malignant mixed müllerian tumors of the ovary. Zhonghua Yi Xue Za Zhi (Taipei); 2000 Apr;63(4):344-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary.
  • Malignant mixed Müllerian tumor (MMMT) of the ovary is very rare, and to the best of our knowledge, only a few cases have been reported in the literature from Taiwan.
  • We report two recent cases of ovarian MMMT at our hospital.
  • Case 1 was a 59-year-old female with stage IIIC MMMT of the ovary, with a tumor having carcinomatous and sarcomatous elements.
  • The sarcomatous component was composed of a homologous malignant mesenchymal element with conspicuous hyaline globules.
  • The patient died of the disease six months after debulking surgery.
  • Case 2 was a 42-year-old female with ovarian stage IIC MMMT.
  • The patient died of the disease four months after debulking surgery.
  • These two patients both underwent hysterectomy, bilateral salpingo-oophorectomy and omentectomy and both received platinum-based chemotherapy after debulking surgery.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820916.001).
  • [ISSN] 0578-1337
  • [Journal-full-title] Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi (Taipei)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] CHINA
  •  go-up   go-down


51. Nechushtan H, Peretz T: [Tamoxifen and breast cancer]. Harefuah; 2002 Aug;141(8):718-20, 761, 760
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently it is the most widely used agent for first line treatment against hormone sensitive metastatic breast cancer and the only approved hormonal agent for adjuvant treatment of organ confined breast cancer.
  • Furthermore, its uses have been extended for the treatment of intraductal breast carcinoma patients.
  • Moreover, it has been shown that for most women transvaginal ultrasound is an ineffective screening method for the early detection of uterine carcinomas.
  • It is important, however, to notice that long term tamoxifen treatment can cause metastatic uterine cancer--not only carcinomas but also sarcomas (mainly malignant mixed mesodermal tumors.
  • This is specifically for long term tamoxifen users (more than the usually recommended five years), women with a higher chance of having uterine carcinomas (namely very high body weight, strong family history) and women with a high index of suspicion as carriers of a BRCA mutation.
  • Until new second generation SERMs and aromatase inhibitors are shown to possess better anti-cancer abilities than tamoxifen, this drug will remain in wide use, however, we must not overlook its possible rare side effects.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Selective Estrogen Receptor Modulators / therapeutic use. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12222137.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 10
  •  go-up   go-down


52. Behtash N, Hashemi R, Karimi Zarchi M: Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):163-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study evaluated tumor characteristics and survival in women with breast cancer who subsequently developed uterine cancer.
  • Two cancers were malignant mixed Mullerian tumors of the uterus (MMMT), 2 were endometrioid adenocarcinomas, and one was a papillary clear cell carcinoma.
  • The endometrial cancers occurred 2-11 years after initial treatment for the breast cancers.
  • At laparotomy of one patient, an advanced stage MMMT was found with diffused peritoneal spread and ascites.
  • In spite of the surgery, she died of disease, 3 months later.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Selective Estrogen Receptor Modulators / adverse effects. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469647.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


53. Cryns P, Roofthooft NJ, Tjalma WA: Malignant mixed müllerian tumor of the ovary and false negative punctures. Eur J Gynaecol Oncol; 2003;24(1):70-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of the ovary and false negative punctures.
  • Malignant mixed müllerian tumour (MMMT) of the ovary is a rare and aggressive tumour with a poor prognosis.
  • We present a case of a 57-year-old woman with a large pelvic mass, omental cake, ascites and pleural effusions, clinically highly suspect of an ovarian neoplasm.
  • Paracentesis and ultrasound-guided biopsy of the ovary were negative for malignant disease.
  • The latter gave a histopathologic diagnosis of an endometrioid adenocarcinoma of the ovary.
  • However after cytoreductive surgery anatomopathologic examination revealed a malignant mixed müllerian tumour of the ovary with heterologous differentiation.
  • Adjuvant chemotherapy, active against the sarcomatous and the carcinomatous component, was given.
  • At present the patient is well and disease free 35 months after the initial diagnosis.
  • Cytological examination of ascites may be negative in the presence of malignant disease.
  • If a tumour consists of two components, puncture can miss one, which may lead to undertreatment.
  • [MeSH-major] Adenocarcinoma / pathology. Mixed Tumor, Malignant / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. False Negative Reactions. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691322.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. Hudelist G, Unterrieder K, Kandolf O, Alpi G, Pucher S, Pollak G, Czerwenka K, Keckstein J: Malignant mixed Müllerian tumor with heterologous component arising in the fallopian tube--a case report. Eur J Gynaecol Oncol; 2006;27(5):509-12
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumor with heterologous component arising in the fallopian tube--a case report.
  • Primary malignant mixed Müllerian tumors (MMMTs) of the fallopian tube are rarities in gynecologic oncology with only 26 cases of MMMTs with a heterologous component reported thus far.
  • We report a case of FIGO Stage II primary MMMT of the fallopian tube with a heterologous tumor portion in an 80-year-old woman presenting with abdominal discomfort at the time of primary diagnosis.
  • After performance of total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy follow-up examination three months postoperatively did not show signs of disease recurrence.
  • The patient finally presented six months after the initial diagnosis with extensive intraabdominal metastasis and died several days thereafter.
  • The efficacy of chemotherapy and radiation remains to be defined in future studies.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Mixed Tumor, Mullerian / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139989.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


55. Allam-Nandyala P, Bui MM, Caracciolo JT, Hakam A: Squamous cell carcinoma and osteosarcoma arising from a dermoid cyst--a case report and review of literature. Int J Clin Exp Pathol; 2010;3(3):313-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rare case of multiple malignant tumors (poorly differentiated squamous cell carcinoma and high grade osteosarcoma) arising in an ovarian dermoid cyst of a 55 year old female is reported.
  • To the best of our knowledge, this is the first well documented example of such an unusual combination of tumors arising in a dermoid cyst.
  • The osteosarcoma and squamous cell carcinoma appear to arise in the background of benign teratomatous environment of a dermoid cyst rather than from "pure" mixed mesodermal tumors of the ovary.
  • The tumors did not appear to have well demarcated boundaries with a junction or close intermingling of both cell types, features less favorable for collision tumor or carcinosarcoma.
  • Despite extensive surgery with negative surgical margins and combination chemotherapy, the patient had recurrence of the tumor within four months and she died secondary to septicemia to chemotherapy and bilateral pulmonary emboli shortly after.
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Ovary / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):410-3 [12759630.001]
  • [Cites] Acta Pathol Jpn. 1981 Jul;31(4):681-8 [7282367.001]
  • [Cites] Gynecol Oncol. 1990 Apr;37(1):143-7 [2182405.001]
  • [Cites] Indian J Cancer. 1993 Sep;30(3):140-2 [8300145.001]
  • [Cites] Saudi Med J. 2009 Apr;30(4):524-8 [19370280.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):89-91 [10374685.001]
  • [Cites] Obstet Gynecol. 1954 Nov;4(5):567-71 [13214667.001]
  • [Cites] Cancer. 1961 Sep-Oct;14:989-1000 [13752348.001]
  • [Cites] BMC Cancer. 2006;6:47 [16509974.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):519-21 [8763274.001]
  • (PMID = 20224730.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2836509
  • [Keywords] NOTNLM ; Malignant dermoid / osteosarcoma / squamous cell carcinoma / teratoma
  •  go-up   go-down


56. Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group: Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst; 2005 Mar 2;97(5):375-84
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
  • BACKGROUND: Tamoxifen treatment of breast cancer is associated with an increased risk of endometrial cancer, but tamoxifen-related risks of endometrial cancer are unclear in premenopausal women, in long-term users of tamoxifen, and in women for whom several years have passed since ending treatment.
  • METHODS: We compared treatment information on 813 case patients who had endometrial cancer after their diagnosis for breast cancer and 1067 control patients who had breast cancer but not subsequent endometrial cancer.
  • RESULTS: Overall, tamoxifen treatment, compared with no treatment, was associated with an increased risk of endometrial cancer (odds ratio [OR] = 2.4; 95% confidence interval [CI] = 1.8 to 3.0).
  • Risk increased statistically significantly (P(trend)<.001) with duration of treatment (for > or =5 years of treatment compared with no treatment, OR = 3.6, 95% CI = 2.6 to 4.8).
  • As an indication of background levels of treatment, 16% of control patients received 5 years or more of treatment.
  • Risk of endometrial cancer adjusted for treatment duration did not diminish in follow-up to at least 5 years after the last treatment ended.
  • Ever treatment with tamoxifen was associated with a much greater risk of Mullerian and mesodermal mixed endometrial tumors (OR = 13.5, 95% CI = 4.1 to 44.5) than of adenocarcinoma (OR = 2.1, 95% CI = 1.6 to 2.7) or clear cell and papillary serous tumors (OR = 3.1, 95% CI = 0.8 to 17.9).
  • CONCLUSIONS: There is an increasing risk of endometrial cancer associated with longer tamoxifen treatment, extending well beyond 5 years.
  • The increased risk of endometrial cancer associated with tamoxifen treatment should be considered clinically for both premenopausal and postmenopausal women during treatment and for at least 5 years after the last treatment.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Endometrial Neoplasms / chemically induced. Estrogen Receptor Modulators / adverse effects. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Case-Control Studies. England. Female. Humans. Logistic Models. Middle Aged. Mixed Tumor, Mesodermal / chemically induced. Mixed Tumor, Mullerian / chemically induced. Odds Ratio. Risk Assessment. Risk Factors. Selective Estrogen Receptor Modulators / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741574.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


57. Arenas LF, Fontes DA, Pereira EM, Hering FL: Sarcomatoid carcinoma with osseous differentiation in the bladder. Int Braz J Urol; 2006 Sep-Oct;32(5):563-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With disputed nomenclature, the tumor has been described previously under a variety of names such as sarcomatoid carcinoma, pseudosarcoma, malignant mixed mesodermal/Müllerian tumor, metaplastic carcinoma and spindle cell carcinoma.
  • This malignancy represents 0.3% of all bladder tumors and has an aggressive behavior yielding a poor prognosis despite radio and chemotherapy.
  • CASE REPORT: An 81 y/o man presented with a transitional cell carcinoma and underwent a transurethral resection.
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aged, 80 and over. BCG Vaccine / therapeutic use. Cystectomy. Fatal Outcome. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / surgery. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081326.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


58. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ: Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):786-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
  • PURPOSE: To determine the survival outcomes, prognostic factors, and patterns of failure in patients with malignant mixed Müllerian tumor (MMMT) of the uterus.
  • METHODS AND MATERIALS: Between 1954 and 1998, 300 patients with clinical Stage I-III MMMT of the uterus were treated with curative intent at The University of Texas M. D.
  • Their hospital records were reviewed to obtain patient and tumor characteristics; details of surgery, radiotherapy (RT), and chemotherapy; and long-term outcome.
  • Forty-eight patients received adjuvant chemotherapy.
  • Women who were postmenopausal or had a history of prior pelvic RT, pain at presentation, clinical Stage II-III disease, uterine enlargement (>/=12 weeks), or an abnormal Papanicolaou smear finding had a significantly poorer prognosis than the other patients in the series.
  • Of the 273 patients who underwent surgery, those who had positive abdominal washings, uterine length >10 cm, or extrauterine spread of disease to the cervix, adnexa, or peritoneum had a significantly worse prognosis than the other patients.
  • At 5 years, the rates of pelvic and distant disease recurrence for the entire group of 300 patients were 38% and 57%, respectively.
  • However, patients treated with pelvic RT had a longer mean time to any distant relapse (17.3 vs. 7.0 months, p = 0.001) than patients treated with surgery alone.
  • The use of adjuvant chemotherapy did not correlate with the survival rate or rate of distant metastasis.
  • CONCLUSION: Adjuvant pelvic RT decreased the risk of pelvic recurrence and may delay the appearance of distant metastases after hysterectomy for MMMT.
  • As more effective systemic chemotherapy is developed to control microscopic distant disease, the role of RT in controlling locoregional disease in the pelvis and abdomen may become more important.
  • Future research should consider programs that integrate surgery, RT, and chemotherapy to maximize the probability of cure.
  • [MeSH-major] Mixed Tumor, Malignant / mortality. Mixed Tumor, Mullerian / mortality. Uterine Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Postmenopause. Postoperative Complications. Prognosis. Radiation Injuries / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R: A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol; 2003 Sep;90(3):529-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.
  • OBJECTIVE: The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers.
  • METHODS: Women with advanced or recurrent MMMT were treated every 28 days with cisplatin (75 mg/m(2)), ifosfamide (1.2 gm/m(2)), and mesna (240 mg/m(2)).
  • Treatment continued until disease progression or for six courses in the case of nonmeasurable disease.
  • RESULTS: Sixteen patients received 1-10 cycles; 2 died of disease progression after 1 cycle; 3 stopped after 1 cycle because of toxicity.
  • Of 6 with measurable disease, 2 had a partial response, 1 had stable disease (SD), and 3 had progression (RR 33%).
  • Of 5 patients without measurable disease, 4 received 6 cycles; 1 received 4 cycles.
  • Four died of recurrent disease and 1 was without disease 6.5 years after treatment.
  • At 7.5 months, only 1 with measurable disease was still living.
  • CONCLUSION: Although the combination of cisplatin, ifosfamide, and mesna in patients with MMMT had moderate activity, the high toxicity and short response duration in this uncommon, aggressive malignancy suggest that this regiment continues to be a disappointing treatment choice for uterine MMMT.
  • HER-2/Neu, Abl, or PDGFR-beta expression may be of value in order to investigate novel multimodality treatment strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2004 Apr;93(1):272-3; author reply 273-4 [15047252.001]
  • (PMID = 13678720.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


60. Huang YT, Huang KG, Ueng SH, Shaw SW: Irradiation-induced uterine malignant mixed müllerian tumor. Taiwan J Obstet Gynecol; 2006 Dec;45(4):353-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irradiation-induced uterine malignant mixed müllerian tumor.
  • OBJECTIVE: To report a case of a patient with cervical squamous cell carcinoma stage IIIB who was diagnosed with malignant mixed müllerian tumor (MMMT) 5 years after radiotherapy.
  • CASE REPORT: A 57-year-old female patient with cervical squamous cell carcinoma FIGO stage IIIB received pelvic irradiation for her disease.
  • At 60 months, Papanicolaou smear revealed abnormal cancer cells and secondary MMMT was diagnosed.
  • The patient underwent surgical treatment followed by chemotherapy.
  • For patients with any types of symptoms, aggressive and immediate investigation is suggested in order to detect possible occult malignancies.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / radiotherapy. Mixed Tumor, Mullerian / etiology. Neoplasms, Radiation-Induced / diagnosis. Uterine Cervical Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175499.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Kourea HP, Adonakis G, Androutsopoulos G, Zyli P, Kourounis G, Decavalas G: Fallopian tube malignant mixed müllerian tumor (carcinosarcoma): a case report with immunohistochemical profiling. Eur J Gynaecol Oncol; 2008;29(5):538-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube malignant mixed müllerian tumor (carcinosarcoma): a case report with immunohistochemical profiling.
  • We report a case of malignant mixed müllerian tumor (MMMT) (carcinosarcoma) of the right fallopian tube in a 69-year-old woman presenting with abdominal pain and an adnexal mass.
  • The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, received adjuvant chemotherapy and is without evidence of disease 12 months postoperatively.
  • The tumor involved the fallopian tube and was composed of in situ and invasive high-grade serous and undifferentiated carcinoma, leiomyosarcoma, rhabdomyosarcoma and undifferentiated sarcoma.
  • The expression of mesothelial-associated antigens WT1, calretinin and HBME in MMMT likely reflects the common embryologic derivation of the mesothelium and urogenital ridge.
  • Loss of nuclear WT1 expression in the mesenchymal component may be involved in MMMT tumorigenesis.
  • [MeSH-minor] Aged. Antigens, CD56 / analysis. Antigens, CD57 / analysis. Calbindin 2. Female. Humans. Immunohistochemistry. S100 Calcium Binding Protein G / analysis. Tumor Suppressor Protein p53 / analysis. WT1 Proteins / analysis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051831.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antigens, CD57; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins
  • [Number-of-references] 15
  •  go-up   go-down


62. Chao KC, Wang PH, Chang CC, Lai CR, Ng HT: Establishment and characterization of a cell line, MT-213-VGH, isolated from a mixed müllerian tumor of the uterus. Acta Cytol; 2001 Sep-Oct;45(5):683-90
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell line, MT-213-VGH, isolated from a mixed müllerian tumor of the uterus.
  • OBJECTIVE: To establish a cell line from a woman with malignant mixed müllerian tumor of the uterus and to examine the biologic properties of this cell line (MT-213-VGH).
  • Histologic staining of mixed müllerian (mesodermal) tumor (MMMT) cells was performed with May-Grünwald-Giemsa and hematoxylin and eosin stain.
  • After more than 20 passages, cells were used to estimate the population-doubling time and colony-forming efficiency of MMMT cells.
  • The cell line exhibited considerable variation in the degree of sensitivity to diverse chemotherapy drugs in vitro.
  • RESULTS: MMMT cells containing antigens for vimentin and myoglobin were detected, but those for CA-125, carcinoembryonic antigen, cytoskeleton, desmin, epithelial membrane antigen and fibronectin were not found.
  • CONCLUSION: The establishment and availability of the number cell line MT-213-VGH for a malignant mixed müllerian tumor of the uterus should assist in research on new methods of managing this type of gynecologic cancer.
  • [MeSH-major] Mixed Tumor, Mullerian. Tumor Cells, Cultured. Uterine Neoplasms

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11575644.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


63. Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF: Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer; 2001 Apr 15;91(8):1437-43
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus.
  • BACKGROUND: The role of adjuvant therapy in the management of patients with malignant mixed Müllerian tumors (MMMT) of the uterus has not been defined.
  • The outcome of planned multimodality therapy for patients with apparent early stage disease was assessed.
  • METHODS: A pilot study was performed on 38 patients with clinical Stage I or II MMMTs of the uterus who were offered treatment according to a standard protocol.
  • The protocol consisted of removal of the uterus, fallopian tubes, and ovaries and surgical staging followed by tailored radiation therapy and chemotherapy, consisting of cisplatin and epirubicin.
  • RESULTS: The overall survival was 74% (28 of 38 patients), with a mean duration of follow-up for survivors of 55 months (range, 17-121 months).
  • The mean time to death from disease was 26 months (range, 7-87 months).
  • The survival rate for those patients who completed treatment according to the multimodality protocol was 95% (20 of 21 patients), with a disease free survival rate of 90% (19 of 21 patients).
  • The overall survival of patients who did not receive the recommended treatment protocol for various reasons was 47% (8 of 17 patients).
  • An analysis of survival curves demonstrated that there was a significant survival advantage for those patients who completed the treatment according to the multimodality protocol (P = 0.01).
  • CONCLUSIONS: In this pilot study, patients with clinical Stage I or II MMMTs who underwent surgical staging and aggressive adjuvant radiation and chemotherapy had an excellent survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / surgery. Uterine Neoplasms / radiotherapy. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11301390.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F: Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol; 2000 Aug;78(2):181-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Duration of Tx therapy was recorded when available, and its correlation with endometrial pathology was assessed.
  • Nine cancers were well-differentiated endometrioid adenocarcinomas, and 24 were moderately or poorly differentiated, of which 13 had nonendometrioid components (serous, clear cell, MMMT).
  • The shortest average duration of Tx therapy (2.5 years) was found in patients with inactive/atrophic endometria and the longest (6.8 years) in patients with endometrial cancer.
  • The endometrial cancers were often high-grade and invasive tumors.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrium / drug effects. Endometrium / pathology. Estrogen Receptor Modulators / adverse effects. Estrogen Receptor Modulators / therapeutic use. Tamoxifen / adverse effects. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Polyps / chemically induced. Polyps / pathology. Retrospective Studies. Uterine Diseases / chemically induced. Uterine Diseases / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10926800.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


65. Ben-Shachar I, Pavelka J, Cohn DE, Copeland LJ, Ramirez N, Manolitsas T, Fowler JM: Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol; 2005 Mar;105(3):487-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The charts of all patients who presented for surgery for endometrial cancer between March 1997 and July 2003 were analyzed for demographic data, final tumor histology, grade, stage, and complications.
  • Preoperatively, 181 (52%) were identified with grade 1 disease, with a mean age of 61 years (range 27-89).
  • Surgical staging (pelvic +/- para-aortic lymphadenectomy) was performed in 82% of cases and was omitted only in cases when disease was apparently confined to the endometrium and surgical risk was high.
  • In comparison of pre- and postoperative histology, 19% of patients were upgraded, with 15% grade 2, 0.5% grade 3, 2.5% serous or clear cell, and 1% mixed mesodermal tumor.
  • No patients with stage Ia-IIb endometrioid cancer received adjuvant teletherapy or chemotherapy.
  • Four patients with low-risk uterine features were found to have extrauterine disease.
  • Twelve percent of patients received adjuvant therapy, and 17% avoided teletherapy and/or chemotherapy based on surgical staging.
  • CONCLUSION: Surgical staging in patients presenting with grade 1 endometrial cancer significantly impacted postoperative treatment decisions in 29% of patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aorta. Biopsy. Combined Modality Therapy. Dilatation and Curettage. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pelvis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738013.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Azevedo P, Verschraegen CF, Kavanagh JJ, Kudelka AP, Freedman RS, Lu K, Deavers MT: Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. Eur J Gynaecol Oncol; 2001;22(5):319-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mesodermal / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11766729.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement